Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Subtractive Interaction Proteomics Reveal a Network of Signaling Pathways Activated By an Oncogenic Transcription Factor in High Risk AML

Claudia Chiriches, PhD, Nathalie Guillen, PhD, Michal Rokicki, Carol Guy, Afsar Mian, PhD, Oliver G. Ottmann, MD, Martin Ruthardt

Blood (2018) 132 (Supplement 1): 3917.

https://doi.org/10.1182/blood-2018-99-116631

Published: 2018

Journal Articles

A Network of Activated Cancer Signaling Pathways in a High Risk Subgroup of Acute Myeloid Leukemia Targetable By SRC-Kinase Inhibitors

Claudia Chiriches, PhD, Dilawar Khan, PhD, Nathalie Guillen, PhD, Michal Rokicki, Carol Guy, Afsar Mian, PhD, Oliver G. Ottmann, MD, Martin Ruthardt, MD

Blood (2016) 128 (22): 2746.

https://doi.org/10.1182/blood.V128.22.2746.2746

Published: 2016

Journal Articles

Transphosphorylation of Endogenous BCR Mediates the Effect of T315I on the Transformation Potential of BCR/ABL

Afsar Mian, PhD, Isabella Haberbosch, Oliver G. Ottmann, MD, Martin Ruthardt, MD

Blood (2014) 124 (21): 4523.

https://doi.org/10.1182/blood.V124.21.4523.4523

Published: 2014

Journal Articles

The Functional Interplay Between the t(9;22)-Associated Fusion Proteins BCR/ABL and ABL/BCR in Philadelphia Chromosome Positive Acute Lymphatic Leukemia

Afsar Mian, PhD, Anahita Rafiei, Claudia Oancea, PhD, Oliver G. Ottmann, MD, Martin Ruthardt, MD

Blood (2014) 124 (21): 2402.

https://doi.org/10.1182/blood.V124.21.2402.2402

Published: 2014

Journal Articles

PF-114, a Novel Selective Pan BCR/ABL Inhibitor Targets The T315I and Suppress Models Of Advanced Ph+ ALL

Afsar Mian, PhD, Anahita Rafiei, Anna Metodieva, Isabella Haberbosch, Alexey Zeifman, Ilya Titov, Victor Stroylov, Oleg Stroganov, Fedor Novikov, Oliver G. Ottmann, MD, Ghermes Chilov, Martin Ruthardt, MD

Blood (2013) 122 (21): 3907.

https://doi.org/10.1182/blood.V122.21.3907.3907

Published: 2013

Journal Articles

The Reciprocal t(9;22) p96 ABL/BCR fusion Protein Eenhances the Transformation Potential of BCR/ABL and Increases Therapy Resistance in Models of Ph+ Acute Lymphatic Leukemia

Anahita Rafiei, Afsar Mian, PhD, Anna Metodieva, Claudia Oancea, Hubert Serve, MD, Heike Pfeifer, MD, Oliver G. Ottmann, MD, Martin Ruthardt, MD

Blood (2012) 120 (21): 3539.

https://doi.org/10.1182/blood.V120.21.3539.3539

Published: 2012

Journal Articles

Prominin-1/CD133 Is Involved in the Lineage Decision As Well As a in the Sensitivity to Molecular Therapy in Ph+ Acute Lymphatic Leukemia.

Anna T. Metodieva, Heike Pfeifer, MD, Afsar Mian, PhD, Anja Vogel, Hubert Serve, Prof. Dr. med., Oliver G. Ottmann, MD, Martin Ruthardt, MD

Blood (2012) 120 (21): 2579.

https://doi.org/10.1182/blood.V120.21.2579.2579

Published: 2012

NARROW

Subtractive Interaction Proteomics Reveal a Network of Signaling Pathways Activated By an Oncogenic Transcription Factor in High Risk AML

A Network of Activated Cancer Signaling Pathways in a High Risk Subgroup of Acute Myeloid Leukemia Targetable By SRC-Kinase Inhibitors

Transphosphorylation of Endogenous BCR Mediates the Effect of T315I on the Transformation Potential of BCR/ABL

The Functional Interplay Between the t(9;22)-Associated Fusion Proteins BCR/ABL and ABL/BCR in Philadelphia Chromosome Positive Acute Lymphatic Leukemia

PF-114, a Novel Selective Pan BCR/ABL Inhibitor Targets The T315I and Suppress Models Of Advanced Ph+ ALL

The Reciprocal t(9;22) p96 ABL/BCR fusion Protein Eenhances the Transformation Potential of BCR/ABL and Increases Therapy Resistance in Models of Ph+ Acute Lymphatic Leukemia

Prominin-1/CD133 Is Involved in the Lineage Decision As Well As a in the Sensitivity to Molecular Therapy in Ph+ Acute Lymphatic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Subtractive Interaction Proteomics Reveal a Network of Signaling Pathways Activated By an Oncogenic Transcription Factor in High Risk AML

A Network of Activated Cancer Signaling Pathways in a High Risk Subgroup of Acute Myeloid Leukemia Targetable By SRC-Kinase Inhibitors

Transphosphorylation of Endogenous BCR Mediates the Effect of T315I on the Transformation Potential of BCR/ABL

The Functional Interplay Between the t(9;22)-Associated Fusion Proteins BCR/ABL and ABL/BCR in Philadelphia Chromosome Positive Acute Lymphatic Leukemia

PF-114, a Novel Selective Pan BCR/ABL Inhibitor Targets The T315I and Suppress Models Of Advanced Ph+ ALL

The Reciprocal t(9;22) p96 ABL/BCR fusion Protein Eenhances the Transformation Potential of BCR/ABL and Increases Therapy Resistance in Models of Ph+ Acute Lymphatic Leukemia

Prominin-1/CD133 Is Involved in the Lineage Decision As Well As a in the Sensitivity to Molecular Therapy in Ph+ Acute Lymphatic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only